These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 31767474)

  • 1. Local and regional treatment response by
    van Diessen JNA; La Fontaine M; van den Heuvel MM; van Werkhoven E; Walraven I; Vogel WV; Belderbos JSA; Sonke JJ
    Radiother Oncol; 2020 Feb; 143():30-36. PubMed ID: 31767474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regional Lymph Node Uptake of [(18)F]Fluorodeoxyglucose After Definitive Chemoradiation Therapy Predicts Local-Regional Failure of Locally Advanced Non-Small Cell Lung Cancer: Results of ACRIN 6668/RTOG 0235.
    Markovina S; Duan F; Snyder BS; Siegel BA; Machtay M; Bradley JD
    Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):597-605. PubMed ID: 26461002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pretreatment 18-FDG-PET/CT parameters can serve as prognostic imaging biomarkers in recurrent NSCLC patients treated with reirradiation-chemoimmunotherapy.
    Grambozov B; Kalantari F; Beheshti M; Stana M; Karner J; Ruznic E; Zellinger B; Sedlmayer F; Rinnerthaler G; Zehentmayr F
    Radiother Oncol; 2023 Aug; 185():109728. PubMed ID: 37301259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor to liver maximum standardized uptake value ratio of FDG-PET/CT parameters predicts tumor treatment response and survival of stage III non-small cell lung cancer.
    Zhang P; Chen W; Zhao K; Qiu X; Li T; Zhu X; Sun P; Wang C; Song Y
    BMC Med Imaging; 2023 Aug; 23(1):107. PubMed ID: 37582701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitivity analysis of FDG PET tumor voxel cluster radiomics and dosimetry for predicting mid-chemoradiation regional response of locally advanced lung cancer.
    Duan C; Chaovalitwongse WA; Bai F; Hippe DS; Wang S; Thammasorn P; Pierce LA; Liu X; You J; Miyaoka RS; Vesselle HJ; Kinahan PE; Rengan R; Zeng J; Bowen SR
    Phys Med Biol; 2020 Oct; 65(20):205007. PubMed ID: 33027064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic patterns on [
    Holzgreve A; Taugner J; Käsmann L; Müller P; Tufman A; Reinmuth N; Li M; Winkelmann M; Unterrainer LM; Nieto AE; Bartenstein P; Kunz WG; Ricke J; Belka C; Eze C; Unterrainer M; Manapov F
    Eur J Nucl Med Mol Imaging; 2023 Jul; 50(8):2466-2476. PubMed ID: 36951991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repeated dynamic [
    Wang D; Mo Y; Liu F; Zheng S; Liu H; Li H; Guo J; Fan W; Qiu B; Zhang X; Liu H
    Eur J Nucl Med Mol Imaging; 2024 Jul; ():. PubMed ID: 38953934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intraepithelial tumor-infiltrating lymphocytes shape loco-regional PET/CT spread of locally advanced cervical cancer.
    Del M; Illac C; Morisseau M; Angeles MA; Ducassou A; Betrian S; Bataillon G; Ferron G; Chantalat E; Gabiache E; Martinez A
    Int J Gynecol Cancer; 2024 Apr; 34(4):490-496. PubMed ID: 38471676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PET/CT in treatment response assessment in lung cancer. When should it be recommended?
    Bin Essa N; Kaplar Z; Balaji N; Alduraibi A; Bomanji J; Groves AM; Lilburn DML; Navani N; Fraioli F
    Nucl Med Commun; 2023 Dec; 44(12):1059-1066. PubMed ID: 37706268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Usefulness of pre- and post-treatment volumetric PET/CT parameters in predicting prognosis and evaluating recurrence for chemoradiotherapy-treated hypopharyngeal cancer.
    Okazaki E; Koyama K; Higashikawa M; Nishida N; Fukuda H
    Eur Arch Otorhinolaryngol; 2024 Aug; ():. PubMed ID: 39141132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of Baseline
    Lucia F; Miranda O; Abgral R; Bourbonne V; Dissaux G; Pradier O; Hatt M; Schick U
    Front Oncol; 2020; 10():678. PubMed ID: 32457839
    [No Abstract]   [Full Text] [Related]  

  • 12. Early PET/CT scans for assessing treatment responses of non-small cell lung cancer for SBRT boost: what to do with scans from multiple scanners.
    McGarry RC; Feddock J; Sinha P; Conrad G; Shelton BJ; Chen L; Arnold SM; Rinehart J
    J Radiosurg SBRT; 2013; 2(4):315-323. PubMed ID: 29296374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant chemotherapy and Avelumab in early stage resectable nonsmall cell lung cancer.
    Tfayli A; Al Assaad M; Fakhri G; Akel R; Atwi H; Ghanem H; El Karak F; Farhat F; Al Rabi K; Sfeir P; Youssef P; Mansour Z; Assi H; Haidar M; Abi Ghanem A; Khalifeh I; Boulos F; Mahfouz R; Youssef B; Zeidan Y; Bejjany R; Khuri F
    Cancer Med; 2020 Nov; 9(22):8406-8411. PubMed ID: 32991781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Observed versus modelled lifetime overall survival of targeted therapies and immunotherapies for advanced non-small cell lung cancer patients - A systematic review.
    Simons M; Ramaekers B; Peeters A; Mankor J; Paats M; Aerts J; van Harten W; Retèl V; Joore M
    Crit Rev Oncol Hematol; 2020 Sep; 153():103035. PubMed ID: 32623070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Locally Advanced, Unresectable Non-Small Cell Lung Cancer.
    Puri S; Saltos A; Perez B; Le X; Gray JE
    Curr Oncol Rep; 2020 Mar; 22(4):31. PubMed ID: 32140986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial.
    Jabbour SK; Berman AT; Decker RH; Lin Y; Feigenberg SJ; Gettinger SN; Aggarwal C; Langer CJ; Simone CB; Bradley JD; Aisner J; Malhotra J
    JAMA Oncol; 2020 Jun; 6(6):848-855. PubMed ID: 32077891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I and extension study of S-1 and carboplatin for previously untreated patients aged 75 years or more with advanced non-small cell lung cancer -TCOG 1101.
    Kasai T; Mori K; Kishi K; Kaburagi T; Hosomi Y; Imai H; Yamada Y; Yomota M; Moriguchi S; Seike M; Minato K; Gemma A;
    Int J Clin Oncol; 2020 May; 25(5):867-875. PubMed ID: 32060768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment patterns and survival after 18F-fluorodeoxyglucose positron emission tomography/computed tomography-guided local consolidation therapy for oligometastatic non-small cell lung cancer: a two-center propensity score-matched analysis.
    Song YQ; Wang N; Qiao Y; He L; Li X; Zhang XF; Yang QK; Wang RZ; He R; Wang CY; Ren YW; Li G; Wang TL
    J Cancer Res Clin Oncol; 2020 Apr; 146(4):1021-1031. PubMed ID: 31980929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS.
    Park K; Vansteenkiste J; Lee KH; Pentheroudakis G; Zhou C; Prabhash K; Seto T; Voon PJ; Tan DSW; Yang JCH; Wang J; Babu KG; Nakayama Y; Alip A; Chua KLM; Cheng JC; Senan S; Ahn YC; Kim TY; Ahn HK; Peters S; Yoshino T; Douillard JY
    Ann Oncol; 2020 Feb; 31(2):191-201. PubMed ID: 31959336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of atezolizumab versus docetaxel and nivolumab in the treatment of non-small cell lung cancer as a second line in France.
    Marine S; Stéphane R; Nicolas P; Felizzi F; Paracha N; Benjamin M; Perol M
    J Med Econ; 2020 May; 23(5):464-473. PubMed ID: 31951770
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.